NueHealth Patients Now Have Access To Advanced Early Cancer Detection Tests

LEAWOOD, Kan., Sep. 19, 2016 /PRNewswire/ -- NueHealth, a privately owned company that delivers value-based healthcare solutions and connects patients directly to physicians through integrated provider networks (IPNs), has announced its partnership with GeneNews, a Canada-based leader in advanced molecular diagnostics and personalized medicine. The three-year partnership agreement elevates NueHealth's commitment to population health management and disease prevention while making GeneNews cancer screening solutions more accessible to patients across the U.S.

Patients who access healthcare through NueHealth's provider networks can take advantage of three different screening types, including ColonSentry®, EARLYCDT®-Lung and Prostate Health Index testing; screenings provide early risk stratification of colorectal cancer, lung cancer and prostate cancer. The screenings utilize a quick and simple blood test and are completed at one of NueHealth's many provider-owned care centers. GeneNews then processes screening samples through the CLIA-certified Innovative Diagnostics Laboratory (IDL) clinical reference lab in Richmond, Va.

"We are excited to partner with NueHealth, a key industry innovator, as they lead the charge toward a healthcare system that focuses on better patient outcomes and greater patient value," said James Howard-Tripp, Chairman & CEO, GeneNews. "Healthcare providers are increasingly being held accountable for their commitment to disease prevention and quality of care. This new, integrated healthcare model is well-aligned with our risk stratification testing, which fills a key void in cancer screening, leading to improved patient adherence, reduced industry costs and better use of healthcare resources."

With its growing national network of integrated providers and low-cost sites of service, NueHealth is working to transform healthcare delivery by focusing on improved outcomes and value-based payment options. The company leverages proprietary technologies, online platforms, and targeted programs and services to give patients, payors and employers access to a simplified model driven by affordable, high-quality, streamlined care. This approach to healthcare aligns seamlessly with GeneNews, whose services give patients and physicians personalized clinical insight and actionable information to improve health outcomes through early diagnosis of disease.

"One of our key drivers at NueHealth is to empower patients—we want them to take control of their health and assume a proactive role when it comes to choosing care," said Dan Tasset, Chairman, NueHealth. "Partnering with companies like GeneNews and offering innovative services like early cancer risk screenings are vital to giving patients the tools they need to stay healthy, and at the same time we're driving down the overarching costs of care, not just for patients but for providers and employers, too. It's our goal to make healthcare simple, affordable, and more accessible, and we believe partnering with GeneNews will help us do that."

To learn more about the innovative consumer programs and services available through NueHealth, visit them online at www.NueHealth.com.  

About NueHealth
NueHealth is putting healthcare back into your hands. Right where it belongs. As your gateway to value-based healthcare, we have engineered an integrated world of primary and specialty care, interactive telehealth and online services, customized wellness and benefit programs, and more. At the center, we've established an unparalleled team of care coordinators to navigate you and your family through a seamless and satisfying experience. Because when we connect you to the right provider at the right time and at the right site of service, we help ensure quality outcomes and effectively drive down costs. Welcome to NueHealth: a simpler world of affordable, high-quality, streamlined healthcare. 

About GeneNews
GeneNews is focused on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The Company's lead product, ColonSentry®, is the world's first blood test to assess an individual's current risk for colorectal cancer. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews can be found at www.GeneNews.com.  

Logo - http://photos.prnewswire.com/prnh/20160208/330660LOGO

SOURCE NueHealth

Related Links

http://www.NueHealth.com